Abstract
Gossypol has demonstrated in vitro effects on cell cycle regulation and anti-tumor activity against mammary carcinoma cell lines. This Phase I/II study assesses both the effect of gossypol on cell cycle regulatory proteins in vivo and the clinical effect. Twenty women with refractory metastatic breast cancer received oral gossypol at daily doses between 30 and 50mg per day. Gossypol plasma levels were measured (n=8) and the modulation of the retinoblastoma (Rb) gene protein and Cyclin D1 was assessed by serial biopsies (n=4). Grade I–II toxicities with gossypol treatment included nausea in 30% of patients, fatigue 15%, emesis 15%, altered taste sensation 15% and diarrhea in 10% of patients. Two of the three patients receiving 50mg/day experienced dose limiting dermatologic toxicity (grade III). One patient had a minor response and two patients had stable disease with >50 decline in serial assessments of the serum tumor markers. Immunohistochemical analysis of cyclin D1 and Rb expression in serial biopsies of four patients revealed both a concurrent decrease in cyclin D1 expression and an increase in nuclear Rb expression in three patients. The maximal tolerated dose (MTD) of gossypol was 40mg/day. Gossypol appears to affect the expression of Rb protein and cyclin D1 in breast cancer metastases at doses achievable, yet had negligible antitumor activity against anthracycline and taxane refractory metastatic breast cancer. The cell cycle regulatory effects of gossypol suggest a potential role for gossypol as a modulating agent in conjunction with other cell cycle specific compounds.
References
Benz CC, Keniry MA, Ford JM, Townsend AJ, Cox FW, Palayoor S, Matlin SA, Hait WN, Cowan KH: Biochemical correlates of the anti-tumor and anti-mitochondrial properties of gossypol enantiomers. Mol Pharmacol 37: 840-847, 1990
Jaroszewski JW, Kaplan O, Cohen JS: Action of gossypol and rhodamine 123 on wild type and multidrug resistant MCF-7 human breast cancer cell 31P nuclear magnetic resonance and toxicity studies. Cancer Res 50: 6936-6943, 1990
Tuszynski GP, Cossu G: Differential cytotoxic effect of gossypol on human melanoma, colon carcinoma and other tissue culture cell lines. Cancer Res 44: 768-771, 1984
Wang Y-C, Rao PN: Effect of gossypol on DNA synthesis and cell cycle progression of mammalian cells in vitro. Cancer Res 44: 35-38, 1984
Rosenberg LJ, Adlakha RC, Desai DM, Rao PN: Inhibition of DNA polymerase alpha by gossypol. Biochim Biphys Acta 886(4): 258-267, 1986
Adlakha RC, Aschorn CL, Chan D, Zwelling LA: Modulation of 4'-(9-acrinidylamino) methanesulfon-m-anisided-induced topoisomerase II medicated DNA cleavage by gossypol. Cancer Res 49(8): 2052-2058, 1989
Rao PN, Wang Y-C, Lotzova E, Khan AA, Rao SP, Stephens LC: Antitumor effects of gossypol on murine tumors. Cancer Chemother Pharmacol 15: 20-25, 1985
Tso WW: Gossypol inhibits Ehrlich ascites tumor cell proliferation. Cancer Lett 24: 257, 1984
Varley JM, Armour J, Swallow JE, Jefferys AJ, Ponder BAJ, T'Ang A, Fung YKT, Brammar WJ, Walker RA: The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumors. Oncogene 4: 725-729, 1989
T'Ang A, Varley JM, Chakraborty S, Muphree L, Fung YKT: Structural rearrangement of the retinoblastoma gene in human breast carcinoma. Science 242: 263-266, 1988
Cooper JA, Whyte P: Rb and the cell cycle: Entrance or exit? Cell 58: 1009-1011, 1989
Lukas J, Pagano M, Staskova Z, Draetta G, Bartek J: Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines. Oncogene 9: 707-718, 1994
Buckley MF, Sweeney JKE, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CKW, Musgrove EA, Sutherland RL: Expression and amplification of cyclin genes in human breast cancer. Oncogene 8: 2127-2133, 1993
Keyomarsi K, Pardee AB: Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci 90: 1112-1116, 1993
Barnes DM, Gillett CE: Cyclin D1 in breast cancer. Breast Cancer Res Treat 52: 1-15, 1998
Ligueros M, Jeoung D, Tang B, Hochhauser D, Reidenberg MM, Sonenberg M: Gossypol inhibition of mitosis, cyclin D1, and Rb protein in human mammary cancer cells and cyclin D1 transfected human fibrosarcoma cells. Br J Cancer 76(1): 21-28, 1997
Reidenberg MM: Studies of gossypol in the treatment of cancer. In: Elsimer M, Coutinho, Paulo Spinola (eds) Reproductive Medicine: A Millennium Review. Parthenon Pub. Group, New York, 1999, pp 305-308
Stein RC, Joseph AEA, Matlin SA, Cunningham D, Ford HT, Coombes RC: A preliminary clinical study of gossypol in advanced human cancer. Cancer Chemother Pharmacol 30: 480-482, 1992
Flack MR, Pyle RG, Mullen NM, Lorenzo B, Wu YW, Knazek RA, Nisula BC, Reidenberg MM: Oral gossypol in the treatment of metastatic adrenal cancer. J Clin Endocrinol Metab 76: 1019-1024, 1993
Bushunow P, Reidenberg M, Wasenko J, Winfield J, Lorenzo B, Lemke S, Himpler B, Corona R, Coyle T: Gossypol treatment of recurrent adult malignant gliomas. J Neuro-Oncol 43: 79-86, 1999
Gehan E: The determination of the number of patients required in a preliminary and follow up trial of a new chemotherapeutic agent. J Chronic Diseases 1061, 13: 346-353
Gilbert NE, O'Reilly JE, Ghange CJG, Lin YC, Brueggmeier RW: Antiproliferative activity of gossypol and gossypolone on human breast cancer cells. Life Sci 57(1): 61-67, 1995
Blackstaffe L, Shelley MD, Fish RG: Cytotoxicity of gossypol enantiomers and its quinone metabolite gossypolone in melanoma cell lines. Mel Res 7: 364-372, 1997
Barnes DM, Gillet CE: Cyclin D1 and breast cancer. Breast Cancer Res Treat 52: 1-15, 1998
Shelley MD, Hartley L, Fish RG, Groundwater P, Morgan JJG, Mort A, Mason M, Evans A: Stereo-specific cytotoxic effects of gossypol enantiomers and gossypolone in tumour cell lines. Cancer Lett 135: 171-180, 1999
Band V, Hoffer AP, Band Rhinehardt AE, Knapp RC, Matlin SA, Anderson DJ: Anti-proliferative effect of gossypol and its optical isomers on human reproductive cancer cell lines. Gynecol Oncol 32: 273-277, 1989
Zhang Y, Kulp SK, Sugimoto Y, Brueggemeier RW, Lin YC: The (-)-enantiomer of gossypol inhibits proliferation of stromal cells derived from human breast adipose tissues by enhancing transforming growth factor Beta 1 production. Int J Oncol 13: 1291-1297, 1998
Sreerama L, Sladek NE: Cellular levels of class 1 and class 3 aldehyde dehydrogenases and certain other drug-metabolizing enzymes in human breast malignancies. Clin Cancer Res 3: 1901-1914, 1997
Rekha GK, Sladek NE: Inhibition of Human Class 3 aldehyde dehydrogenase, and sensitization of tumor cells that express significant amount of this enzyme to oxazaphosphorines, by the naturally occurring compound gossypol. Advances in Experimental medicine and biology. In: Weiner et al. (eds), Enzymology and Molecular Biology of Carbonyl Metabolism 6. Vol 414. Plenum Press, New York, 1996, pp 122-146
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Van Poznak, C., Seidman, A.D., Reidenberg, M.M. et al. Oral Gossypol in the Treatment of Patients with Refractory Metastatic Breast Cancer: A Phase I/II Clinical Trial. Breast Cancer Res Treat 66, 239–248 (2001). https://doi.org/10.1023/A:1010686204736
Issue Date:
DOI: https://doi.org/10.1023/A:1010686204736